Cargando…

Osteoclast inhibitors to prevent bone metastases in men with high-risk, non-metastatic prostate cancer: A systematic review and meta-analysis

BACKGROUND: In advanced prostate cancer, osteoclast inhibitors prevent and palliate skeletal related events associated with bone metastases. However, it is uncertain whether they play a disease-modifying role earlier in the course of the disease. METHODS: Medline, EMBASE, Cochrane Central Register o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hayes, Aimee R., Brungs, Daniel, Pavlakis, Nick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784941/ https://www.ncbi.nlm.nih.gov/pubmed/29370211 http://dx.doi.org/10.1371/journal.pone.0191455

Ejemplares similares

Osteoclast inhibitor treatment among men with metastatic castration-resistant prostate cancer
por: Sonnenburg, Daniel, et al.
Publicado: (2018)

Osteoclasts Are Active in Bone Forming Metastases of Prostate Cancer Patients
por: Roato, Ilaria, et al.
Publicado: (2008)

Tumor- and osteoclast-derived NRP2 in prostate cancer bone metastases
por: Polavaram, Navatha Shree, et al.
Publicado: (2021)

Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical Practice
por: Li, Bob T., et al.
Publicado: (2014)

The Osteoclast Traces the Route to Bone Tumors and Metastases
por: Russo, Sharon, et al.
Publicado: (2022)

The Osteoblastic and Osteoclastic Interactions in Spinal Metastases Secondary to Prostate Cancer
por: Dushyanthen, Sathana, et al.
Publicado: (2013)

Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer
por: El-Amm, Joelle, et al.
Publicado: (2016)

Bone Microenvironment‐Suppressed T Cells Increase Osteoclast Formation and Osteolytic Bone Metastases in Mice
por: Arellano, Danna L., et al.
Publicado: (2022)

The Current Role of Osteoclast Inhibitors in Patients with Prostate Cancer
por: Kozyrakis, Diomidis, et al.
Publicado: (2018)

Osteoclast inhibition by pamidronate in metastatic prostate cancer: a preliminary study.
por: Clarke, N. W., et al.
Publicado: (1991)

Impact of Extraskeletal Metastases on Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer with Bone Metastases
por: Lobo-Martins, Soraia, et al.
Publicado: (2020)

MMP-13 stimulates osteoclast differentiation and activation in tumour breast bone metastases
por: Pivetta, Eliana, et al.
Publicado: (2011)

Alterations in osteoclast function and phenotype induced by different inhibitors of bone resorption - implications for osteoclast quality
por: Neutzsky-Wulff, Anita V, et al.
Publicado: (2010)

Systemic Alterations of Wnt Inhibitors in Patients with Prostate Cancer and Bone Metastases
por: Aufderklamm, Stefan, et al.
Publicado: (2018)

Pathologic fracture and metastatic spinal cord compression in patients with prostate cancer and bone metastases
por: Nieder, Carsten, et al.
Publicado: (2010)

Systematic Review and Meta-Analysis on the Role of Chemotherapy in Advanced and Metastatic Neuroendocrine Tumor (NET)
por: Wong, Matthew H., et al.
Publicado: (2016)

What are the efficacy and safety of bisphosphonates and RANK-ligand-inhibitors for men with prostate cancer and bone metastases? - A Cochrane Review summary with commentary
por: Moretti, Antimo
Publicado: (2021)

Clinical and imaging-based prognostic factors in radioembolisation of liver metastases from colorectal cancer: a retrospective exploratory analysis
por: Willowson, Kathy P., et al.
Publicado: (2017)

Procoxacin bidirectionally inhibits osteoblastic and osteoclastic activity in bone and suppresses bone metastasis of prostate cancer
por: Kong, Depei, et al.
Publicado: (2023)

Observations on Prostatic Cancer with Metastases in Bone
por: Charteris, Alexander A.
Publicado: (1927)

Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer
por: Armstrong, Andrew J., et al.
Publicado: (2019)

Bone targeted therapies for the prevention of skeletal morbidity in men with prostate cancer
por: Saylor, Philip J
Publicado: (2014)

Selenoprotein W ensures physiological bone remodeling by preventing hyperactivity of osteoclasts
por: Kim, Hyunsoo, et al.
Publicado: (2021)

Engineering osteoblastic metastases to delineate the adaptive response of androgen-deprived prostate cancer in the bone metastatic microenvironment
por: Bock, Nathalie, et al.
Publicado: (2019)

Bone Is Not Essential for Osteoclast Activation
por: Fuller, Karen, et al.
Publicado: (2010)

Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature
por: Chan, David L., et al.
Publicado: (2015)

Screening of protein kinase inhibitors identifies PKC inhibitors as inhibitors of osteoclastic acid secretion and bone resorption
por: Sørensen, Mette G, et al.
Publicado: (2010)

Cytoreductive surgery for men with metastatic prostate cancer
por: Katelaris, Nikolas, et al.
Publicado: (2016)

Correction: Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature
por: Chan, David L., et al.
Publicado: (2015)

Bruton's tyrosine kinase (Btk) inhibitor tirabrutinib suppresses osteoclastic bone resorption
por: Ariza, Yuko, et al.
Publicado: (2019)

Micheliolide prevents estrogen deficiency-induced bone loss via inhibiting osteoclast bone resorption
por: Gan, Ziyang, et al.
Publicado: (2023)

Prostate Cancer and Bone Metastases: The Underlying Mechanisms
por: Wong, Sok Kuan, et al.
Publicado: (2019)

Amaranthus mangostanus Inhibits the Differentiation of Osteoclasts and Prevents Ovariectomy-Induced Bone Loss
por: Jeong, Yeon-Hui, et al.
Publicado: (2020)

Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption
por: Chiao, J W, et al.
Publicado: (2000)

Anti-c-fms Antibody Prevents Osteoclast Formation and Bone Resorption in Co-Culture of Osteoblasts and Osteoclast Precursors In Vitro and in Ovariectomized Mice
por: Nara, Yasuhiko, et al.
Publicado: (2020)

The effect of anti-angiogenic agents on overall survival in metastatic oesophago-gastric cancer: A systematic review and meta-analysis
por: Chan, David L., et al.
Publicado: (2017)

Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy
por: Francini, Edoardo, et al.
Publicado: (2021)

Prevention of Wear Particle-Induced Osteolysis by a Novel V-ATPase Inhibitor Saliphenylhalamide through Inhibition of Osteoclast Bone Resorption
por: Qin, An, et al.
Publicado: (2012)

Hedgehog Inhibitors Suppress Osteoclastogenesis in In Vitro Cultures, and Deletion of Smo in Macrophage/Osteoclast Lineage Prevents Age-Related Bone Loss
por: Kohara, Yukihiro, et al.
Publicado: (2020)

Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis
por: Rydzewska, Larysa H.M., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_o25rp5cetkcj89si9angab23uc